Pulmonary Hypertension

Janssen Submits New Drug Application (NDA) to US FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH) - BioSpace Janssen Submits New Drug Application (NDA) to US FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH) - BioSpace Posted: 30 Sep 2020 04:39 AM PDT SOUTH SAN FRANCISCO, Calif. , Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI ® (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults with WHO functional class (FC) II–III, who are currently prescribed oral UPTRAVI but are temporarily unable to take oral therapy. In patients with PAH, interruptions in treatment should be avoided du...

Janssen Submits New Drug Application (NDA) to US FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH) - PRNewswire Janssen Submits New Drug Application (NDA) to US FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH) - PRNewswire Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day - Odessa American Taking a Personalized Approach to Pain Management | - Pulmonary Hypertension News Janssen Submits New Drug Application (NDA) to US FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH) - PRNewswire Posted: 30 Sep 2020 04:00 AM PDT SOUTH SAN FRANCISCO, Calif. , Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. ...

PAH Risk Status – It May Change How You Think About the Future... - Pulmonary Hypertension News PAH Risk Status – It May Change How You Think About the Future... - Pulmonary Hypertension News Posted: 15 Sep 2020 12:36 AM PDT If you have pulmonary arterial hypertension (PAH) – a type of high blood pressure that can have a dangerous impact on your heart and on your lungs – it is important to know your risk status. Understanding your risk status may change how you think about your future. Based on research involving thousands of patients, conducted by the world's leading experts in PAH, risk status is a different way for your doctor to assess your PAH. Unlike PAH tests, risk status provides a more thorough view of your condition. Risk status can provide critical insight for you and your doctor on things like how well your treatments are working and how your PAH may progress in the future. Risk status can also be linked ...